A Novel Healthcare Information Technology Tool to Improve Care in Patients With Atrial Fibrillation (AFCare)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02623517|
Recruitment Status : Completed
First Posted : December 7, 2015
Last Update Posted : August 5, 2022
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||75 participants|
|Official Title:||A Novel Healthcare Information Technology Tool to Improve Care in Patients|
|Study Start Date :||May 2016|
|Actual Primary Completion Date :||July 1, 2021|
|Actual Study Completion Date :||July 1, 2021|
The Enrolled Subjects group will comprise of 75 individuals who will be followed for 12 months for their atrial fibrillation condition. Data will be collected from subjects' devices for 12 months, and any needed changes or additions to therapy will be done. (ie: ablation, pacemaker setting changes, medication control).
The Registry Subjects group will comprise of screened patients who do not exhibit symptoms of atrial fibrillation at the time of screening. The already collected data from the patient's device during the screening visit will be kept and put into a registry.
- The prevalence of atrial fibrillation in patients with CIEDs [ Time Frame: two years ]To establish the prevalence of device detected atrial tachyarrhythmia episodes (most commonly AF) in patients who have device interrogations performed in the Emergency Room by the Geneva Healthcare Patient Population Management Platform
- The prevalence of cardiac electrophysiology referrals from the E.D [ Time Frame: two years ]To establish the prevalence of cardiac electrophysiology referral in a population of patients with cardiac rhythm devices but no Geneva Healthcare Patient Population Management Platform routine interrogation versus routine interrogation in the emergency room.
- The patient population with AF that are treated with catheter ablation [ Time Frame: two years ]
- The patient population with AF that are treated with rate-control therapy [ Time Frame: two years ]
- The patient population with AF that are treated with rhythm control drug therapy [ Time Frame: two years ]
- The patient population with AF that are treated with oral anticoagulation for stroke prophylaxis [ Time Frame: two years ]
- The prevalence of device and lead malfunctions in patients with CIEDs. [ Time Frame: two years ]To investigate the prevalence of device and lead malfunction in a population of patients with cardiac rhythm devices undergoing interrogation by the Geneva Healthcare Patient Population Management Platform.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02623517
|United States, California|
|Sulpizio Cardiovascular Center|
|La Jolla, California, United States, 92037|
|Principal Investigator:||Jonathan Hsu, MD||UC San Diego School of Medicine; Sulpizio Cardiovascular Center|